ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

AZN Astrazeneca Plc

12,028.00
98.00 (0.82%)
30 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Astrazeneca Plc LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change % Change Share Price Shares Traded Last Trade
  98.00 0.82% 12,028.00 1,690,402 16:35:05
Bid Price Offer Price High Price Low Price Open Price
12,032.00 12,036.00 12,142.00 11,994.00 12,108.00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations USD 45.81B USD 5.96B USD 3.8415 31.33 186.55B
Last Trade Time Trade Type Trade Size Trade Price Currency
16:39:04 AT 613 12,028.00 GBX

Astrazeneca (AZN) Latest News (2)

Astrazeneca (AZN) Discussions and Chat

Astrazeneca (AZN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
15:39:0412,028.0061373,731.64AT
15:39:0412,028.0018722,492.36AT
15:39:0012,028.0062475,054.72AT
15:39:0012,028.0017621,169.28AT
15:35:0512,028.00425,051.76O

Astrazeneca (AZN) Top Chat Posts

Top Posts
Posted at 30/5/2024 09:20 by Astrazeneca Daily Update
Astrazeneca Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker AZN. The last closing price for Astrazeneca was 11,930p.
Astrazeneca currently has 1,550,189,338 shares in issue. The market capitalisation of Astrazeneca is £186,549,784,935.
Astrazeneca has a price to earnings ratio (PE ratio) of 31.33.
This morning AZN shares opened at 12,108p
Posted at 30/5/2024 10:27 by philanderer
Goldman starts AstraZeneca with 'buy' - price target 15,200 pence
Posted at 22/5/2024 11:27 by philanderer
Stifel raises AstraZeneca price target to 13,700 (12,800) pence - 'buy'
Posted at 08/5/2024 06:24 by hotfinance14
Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Berenberg expects Astrazeneca to state a new revenue ambition at its 21 May investor day, highlighting confidence in growth to 2030 from already visible assets. High single-digit growth would equate to a roughly $75.0bn-80.0bn top line and approximately 20% upside to consensus, it noted.

"On our estimates, global large pharma is on track to grow sales at 4% pa for 2026-30 (range -2% to 13%) with an average 2025 P/E of 16.6x (range 7-42x). High single-digit growth would put Astrazeneca at the top end of the non-obesity range and warrant a multiple above 20x, in our view," said Berenberg.

The German bank stated it was raising its price target to reflect "recent, positive pipeline updates", which implies a 2025 price-to-earnings ratio of 19x.

"We reiterate our 'buy' recommendation as positive pipeline momentum through to 2025 has the potential to unlock sales upgrades and share price upside," said Berenberg.

"Astrazeneca offers top-tier sales growth at an attractive valuation, with a P/E of 17.4x 2025E versus an EU sector average of 15.7x and EV/NPV of 1.05x versus an average of 1.01x"
Posted at 07/5/2024 13:06 by philanderer
Berenberg raises AstraZeneca price target to 13,000 (12,000) pence - 'buy'
Posted at 08/4/2024 15:02 by actomox
(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.

The Cambridge, England-based pharmaceutical company said Ultomiris and Soliris "can transform" patient outcomes in sufferers of rare neurological diseases.

Astra will present data from its rare neurology portfolio at the American Academy of Neurology meeting in Denver, Colorado next week.

(And, as usual, the share price declines on good news)
Posted at 08/4/2024 14:47 by wad collector
Really?
Found 22 results:

Blackhorse23 - 08 Apr 2024 - 11:28:43 - 6011 of 6012 AstraZeneca - AZN
Money moved to APH
Blackhorse23 - 05 Apr 2024 - 09:16:44 - 6009 of 6012 AstraZeneca - AZN

Blackhorse23 - 21 Mar 2024 - 08:47:26 - 6002 of 6012 AstraZeneca - AZN
Money moving to APH [LSE] , excellent profitable healthcare company
Blackhorse23 - 21 Feb 2024 - 14:26:56 - 5995 of 6012 AstraZeneca - AZN
Money moving to APH , excellent growth health care company
Blackhorse23 - 12 Feb 2024 - 11:37:36 - 5981 of 6012 AstraZeneca - AZN
Money moving to APH
Blackhorse23 - 29 Jan 2024 - 15:32:08 - 5957 of 6012 AstraZeneca - AZN

Blackhorse23 - 19 Jan 2024 - 11:52:35 - 5956 of 6012 AstraZeneca - AZN
Ha ha hxxps://www.alliancepharmaceuticals.com/
Blackhorse23 - 18 Jan 2024 - 14:23:42 - 5954 of 6012 AstraZeneca - AZN
Bought some APH today
Blackhorse23 - 09 Jan 2024 - 11:01:43 - 5948 of 6012 AstraZeneca - AZN
are they buying APH ??
Posted at 19/3/2024 08:50 by geckotheglorious
Wonder how many Fusion Pharm shareholders were relatively new and benefitted from the 97% premium to 18th March close!

Bound to have been plenty of insider dealing stateside, probably in "Options" to leverage the benefit.

Under the terms of the definitive agreement, AstraZeneca, through a subsidiary, will acquire all of Fusion's outstanding shares pursuant to a plan of arrangement for a price of $21.00 per share in cash at closing plus a non-transferable contingent value right of $3.00 per share in cash payable upon the achievement of a specified regulatory milestone. The upfront cash portion of the consideration represents a transaction value of approximately $2bn, a 97% premium to Fusion's closing market price of $10.64 on 18th March 2024 and an 85% premium to the 30-day volume-weighted average price (VWAP) of $11.37 before this announcement.
Posted at 08/2/2024 16:34 by 1knocker
AZN is still pretty richly priced. I think it should slide a bit more. I may put a limit order in to buy a few more at 93, though that will significantly above my average, currently 58 after a few out and back in round trips a few years back.

AZN does not pay much of a dividend, and I see no catalyst to move the price north at present, so in this uncertain market I shall probably put in my order at 90 and be patient.
Posted at 05/12/2023 17:50 by turvart
AZN now well below the 200 & 50 day moving average, the 200 day MA is approx 11000 area so this is a steal IMO with all the future developments in phase 11 & 111 trials. One aspect I also like is the fact AZN do not stand still and get complacent the company is always striving to get bigger and make regular acquisitions.

AZN was my very first stock I purchased when I was a complete newbie back in 2001 and I paid £17.50 a share back then, look at the growth of this immense stock of which I'm sure will get to £130 by the end of 2024 IMO, AZN was in my portfolio in 2001 at 1750 and still are and has been my best performing stock, just wished I'd have bought more and left them alone re-investing the dividends along the way.

Strong buy IMO.
Posted at 05/7/2023 10:06 by philanderer
Berenberg lowers AstraZeneca target price


A lung cancer treatment from AstraZeneca (AZN) failed to meet high investor expectations but the share price drop is ‘overdone̵7;, says Berenberg.

Analyst Luisa Hector reiterated her ‘buy’ recommendation but lowered her target price slightly from £135 to £133 on the Citywire Elite Companies AAA-rated stock, which rose 2.2%, or 228p, to £106.02 on Tuesday.

The pharmaceutical giant, along with its partner Daiichi Sankyo, announced positive progression-free survival headline data for their lung cancer treatment.

‘The absence of more positive language in the press release, such as “clinically meaningful”, and the occurrence of some fatal interstitial lung disease events missed high investor expectations, resulting in AstraZeneca’s share price falling by 8%,’ said Hector.

She said the future of the drug relies on further testing, which is expected in the next six months.

‘We lower our price target to £133… a much smaller reduction than the share price move of 900p. We think the stock reaction is overdone given the overall strength of AstraZeneca’s pipeline,’ she said.


citywire.com
Astrazeneca share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock